Yahoo! Finance
03-24-2009, 05:43 AM
<b>Yahoo! Finance: Commodity News</b>
CAMBRIDGE, Mass.----AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced a definitive agreement with Biogen Idec, Inc. , for the development and commercialization of AVEO's novel discovery-stage ErbB3-targeted antibodies for the potential treatment of cancer and other diseases.
complete story here... (http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/090324/20090324005213.html?.v=1)
CAMBRIDGE, Mass.----AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced a definitive agreement with Biogen Idec, Inc. , for the development and commercialization of AVEO's novel discovery-stage ErbB3-targeted antibodies for the potential treatment of cancer and other diseases.
complete story here... (http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/090324/20090324005213.html?.v=1)